Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

NVCD

Financiado

Cerrado

Minimally invasive suturing for vascular bore closure and heart defect repair

Cardiovascular diseases (CVDs) remain a major health problem worldwide and a leading cause of mortality, with over annual 18 million deaths. In Europe, CVDs are associated with 4 million deaths and costs of around €210 billion per... ver más

31/01/2027

NOVELRAD LTD

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

NOVELRAD LTD No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-01

HORIZON-EIC-2023-ACCELERATOROPEN-01: EIC Accelerator Open 2023 Scope:The EIC Accelerator Open has no predefined thematic priorities and is open to proposals in any...

I+D

Cerrada

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

NOVELRAD LTD

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 29 meses Fecha Inicio: 2024-08-01
Fecha Fin: 2027-01-31

Líder del proyecto

NOVELRAD LTD No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiovascular diseases (CVDs) remain a major health problem worldwide and a leading cause of mortality, with over annual 18 million deaths. In Europe, CVDs are associated with 4 million deaths and costs of around €210 billion per year.Many surgeries to treat cardiac conditions are shifting to be minimally invasive and this is a trend expected to continue growing due to its multiple advantages over open interventions. However, as newly developed devices for transcatheter procedures become bigger they also require larger vascular access sites. A couple of devices are used in vascular large-bore closure (e.g. ProGlide from Abbott). However, they are associated with still high vascular and bleeding complications (up to 20%, depending on the operator’s skills). Such complications are linked to longer hospitalizations, unnecessary suffering, and greater healthcare costs (€20k per patient), as well as higher morbidity and mortality.To solve this persistent unmet need in the field of cardiovascular surgery, Novelrad has specifically developed the NVCD closure device. It integrates a proprietary and revolutionary micro-suturing technology that mimics the standard surgical technique, effectively delivering a multipoint continuous suture in a minimally invasive manner. The NVCD is easy to use and enables a safer closure of large bores, potentially reducing complication rates to 3%, saving up to 15 min in the procedure, and bringing important cost savings related to same-day discharge and complications’ management. Importantly, with a single NVCD device large and extra-large bore closure of veins and arteries is possible (up to 30Fr).After obtaining a fully functional prototype of the NVCD and advancing in pre-clinical tests, we now aim to perform a first-in-human (FIH) study and complete the clinical trial required to obtain its CE certification as a Class III medical device. This will be crucial to prepare for industrialization and commercial deployment in Europe and globally.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores